comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 13:30:32 - browse：28335

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： After a drawn out lobbying fight, ARPA

focus

WSS

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Paxlovid should be available without a positive Covid test

Researchers use wearables data and AI to predict preterm birth risk

Would Medicare drug price negotiations stall in a shutdown?

Thousands protest in Iraq for a second day over burning of Quran in Sweden

FDA advisers vote against ALS treatment from BrainStorm

entertainment

comprehensive

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Supreme Court rules employers must be more accommodating of religious observance

Walensky prepares to leave CDC — and Congress — behind

GOP inquiry over gain

DIEP, the 'gold standard' of breast reconstruction, is under threat

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Affirmative action in medical school literally saved lives

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Medical leaders decry Supreme Court decision on affirmative action

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Wikipedia

The strange history of BMI, the body mass index

Listen: Who gets the credit for GLP

Listen: Who gets the credit for GLP

Paxlovid should be available without a positive Covid test

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

GOP inquiry over gain

focus

focus

explore

focus